Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Flybe’s airline has crashed for the second time within three years. This cancelled all flights and caused disruption for thousands of passengers.
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Walkouts are planned for the days leading up to Christmas.
As forecasters warn about severe weather conditions, snow has been spotted in parts of the UK.
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
The UK’s night time tsar has warned that pubs and restaurants will face “criminal” energy costs and that Britain should be prepared for record numbers of closures.
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for